Evidence map›Paper›PMID 34027668›Full record

ArticleJournal of medicinal chemistry2021

Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.

Boshi Huang, Huiqun Wang, Yi Zheng, Mengchu Li, Guifeng Kang, Victor Barreto-de-Souza, Nima Nassehi, Pamela E Knapp, Dana E Selley, Kurt F Hauser and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. GPCR Heterodimers: Implications for Biased Signaling.Handbook of experimental pharmacology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. The crosstalk between 5-HTNeuropharmacology · 2023
    Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Boshi HuangDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Huiqun WangDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Yi ZhengDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Mengchu LiDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Guifeng KangDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Victor Barreto-de-SouzaDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N. 12th Street, Richmond, Virginia 23298, United States.
Nima NassehiDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N. 12th Street, Richmond, Virginia 23298, United States.
Pamela E KnappDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N. 12th Street, Richmond, Virginia 23298, United States.
Dana E SelleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N. 12th Street, Richmond, Virginia 23298, United States.
Kurt F HauserDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N. 12th Street, Richmond, Virginia 23298, United States.ORCID 0000-0001-7886-0332
Yan ZhangDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23298, United States.ORCID 0000-0001-8934-7016
Virginia Commonwealth University · US

Funding

MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injuryR01DA034231 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, KNAPP, PAMELA E · 2013 to 2023
$5.4M
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV InfectionR01DA044855 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, ZHANG, YAN · 2017 to 2021
$2.7M
NIDA NIH HHS R01 DA034231NIDA NIH HHS R01 DA044855
6 · The paper itself

Abstract

Crystal structures of ligand-bound G-protein-coupled receptors provide tangible templates for rationally designing molecular probes. Herein, we report the structure-based design, chemical synthesis, and biological investigations of bivalent ligands targeting putative mu opioid receptor C-C motif chemokine ligand 5 (MOR-CCR5) heterodimers. The bivalent ligand

Indexed as

Drug DesignLigandsAnalgesics, OpioidAnti-HIV AgentsBinding SitesDimerizationHIV-1HumansLeukocytes, MononuclearMaravirocMolecular Docking SimulationMolecular Dynamics SimulationNaltrexonePhytohemagglutininsProtein BindingReceptors, CCR5Analgesics, OpioidAnti-HIV AgentsLigandsMaravirocNaltrexonePhytohemagglutininsReceptors, CCR5Receptors, Opioid, mu

Identifiers

PMID34027668
PMCPMC10548452
OpenAlexW3163978845

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.